Understand the source comparison
PE-22-28 Dosage Mood Enhancement 2026: Clinical Protocol Comparison
Standard Neuroplasticity 300–400 mcg Morning (within 2h of waking) 28 days on, 14 days off Detectable increase by day 10–14 Optimal for first-time researchers. Balances efficacy with tolerability and allows clear assessment of response High-Intensity Research
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Standard Neuroplasticity
- 300–400 mcg
- Morning (within 2h of waking)
- 28 days on, 14 days off
- Detectable increase by day 10–14
- Optimal for first-time researchers. Balances efficacy with tolerability and allows clear assessment of response
- High-Intensity Research
- 500 mcg
- Detectable increase by day 7–10
- Reserved for institutional protocols with daily monitoring. Higher injection site inflammation risk
- Extended Cycle
- 300 mcg
- 56 days on, 21 days off
- Sustained elevation through day 42
- Requires receptor density monitoring. Diminishing returns after day 45 in most models
- Evening Administration
- 300–500 mcg
- Evening (2h before sleep)
- Reduced efficacy vs morning dosing
- Not recommended unless circadian constraints prevent morning dosing. Conflicts with melatonin signaling